Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacokinetics of Ponesimod in Subjects With Symptomatic Chronic GVHD

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 29, 2016

Primary Completion Date

March 2, 2017

Study Completion Date

March 3, 2017

Conditions

Chronic Graft Versus Host Disease

Interventions

DRUG

Ponesimod

Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.